Klaudia Farkas
Szegedi Tudományegyetem
H-index: 32
Europe-Hungary
Top articles of Klaudia Farkas
Szűrő kolonoszkópos vizsgálatok hatékonyságának és biztonságosságának értékelése a Szegedi Tudományegyetemen és a Bács-Kiskun Vármegyei Oktatókórházban 2019 és 2022 között
Orvosi Hetilap
2024/2/11
Analysis of efficacy and safety of colonoscopic screening program at the University of Szeged and the Bács-Kiskun County Teaching Hospital between 2019 and 2022
Orvosi hetilap
2024/2/11
Co-Administration of Proton Pump Inhibitors May Negatively Affect the Outcome in Inflammatory Bowel Disease Treated with Vedolizumab
Biomedicines
2024/1/11
Effectiveness and safety of switching from original infliximab to GP1111 biosimilar in inflammatory bowel diseases-prospective, cohort study
Dermatologic Therapy
2020/11/1
P938 Effectiveness and safety of switching from original infliximab to GP1111 biosimilar in inflammatory bowel diseases–prospective, cohort study
Journal of Crohn's and Colitis
2024/1/1
P1016 Real-world data on sequential therapy in moderate-to-severe UC: Unveiling second-line strategies after anti-TNF failure
Journal of Crohn's and Colitis
2024/1/1
P356 Long-term outcome of UC patients in clinical remission with different level of mucosal activity: real world, retrospective, multicontinental study
Journal of Crohn's and Colitis
2024/1/1
Effectiveness and safety of a third‐line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)
Alimentary Pharmacology & Therapeutics
2024/5
Mette Julsgaard
H-Index: 13
Klaudia Farkas
H-Index: 24
P421 The faecal biomarker LDN-051 is a novel tool for monitoring disease activity and therapeutic response in Inflammatory Bowel Diseases
Journal of Crohn's and Colitis
2024/1/1
P661 Ustekinumab in Crohn’s disease: A three-year multicentre prospective study from Hungary-Assessing efficacy, drug sustainability, and safety
Journal of Crohn's and Colitis
2024/1/1
P674 Real-world experiences of switching to subcutaneous formulation in IBD patients on maintenance vedolizumab treatment
Journal of Crohn's and Colitis
2024/1/1
P560 The impact of reactive point-of-care drug level measurement on the medium-term course of inflammatory bowel disease
Journal of Crohn's and Colitis
2024/1/1
P663 Efficacy of jak inhibitors in inflammatory bowel disease patients with extraintestinal manifestations–Retrospective study
Journal of Crohn's and Colitis
2024/1/1
Long-term outcomes after endoscopic removal of malignant colorectal polyps: results from a 10-year cohort
Endoscopy
2020/4
Accuracy of PanMayo endoscopic score in predicting long-term disease outcomes in ulcerative colitis–a promising scoring system
Endoscopy
2024/4
Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn’s disease patients over three years
2024/3/13
Klaudia Farkas
H-Index: 24
Aron Vincze
H-Index: 22
A fekélyes vastagbélgyulladás gyógyszeres és sebészeti kezelése
Orvosi Hetilap
2024/3/12
Klaudia Farkas
H-Index: 24
Tamás Molnár
H-Index: 3
A Crohn-betegég terápiás stratégiája
Orvosi Hetilap
2024/3/12
Klaudia Farkas
H-Index: 24
Tamás Molnár
H-Index: 3
Accuracy of the Pancolonic Modified Mayo Score in predicting the long-term outcomes of ulcerative colitis: a promising scoring system
Therapeutic Advances in Gastroenterology
2024/3
Plasminogen activator inhibitor 1 is a novel faecal biomarker for monitoring disease activity and therapeutic response in inflammatory bowel diseases
Journal of Crohn's & Colitis
2024/3
